FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL									
OMB Number:	3235-0287								
Estimated average b	urden								
hours por rosponso:	0.5								

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* <u>HANTSON LUDWIG</u>				<u> </u>	2. Issuer Name and Ticker or Trading Symbol ALEXION PHARMACEUTICALS INC							Relationship of Reporting Person(s) to Issuer (Check all applicable) X Director 10% Owner						
(Last)	(F	iret)	(Middle)		ALXN]								X	Officer ((give title		Other (s	pecify
(Last) (First) (Middle) C/O ALEXION PHARMACEUTICALS, INC. 100 COLLEGE STREET					3. Date of Earliest Transaction (Month/Day/Year) 03/29/2017								,	CI	EO	,		
(Street) NEW HAVEN CT 06510					4. If Amendment, Date of Original Filed (Month/Day/Year)							Individual or Joint/Group Filing (Check Applicable Line) X Form filed by One Reporting Person						
(City)	(5	State)	(Zip)											Form fil Person	ed by More	than (One Report	ing
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned																		
1. Title of Security (Instr. 3) 2. Transar Date (Month/Date)					Execution Date,		3. Transaction Code (Instr. 8) 4. Securities Acquired (A) Disposed Of (D) (Instr. 3, 4				1 and 5) Securities Beneficia Owned Fe		s Form ally (D) o ollowing (I) (Ir		Direct I Indirect E str. 4)	7. Nature of Indirect Beneficial Ownership		
								Code	v	Amount	Amount (A) or (D)		e		Reported Fransaction(s) Instr. 3 and 4)		1	(Instr. 4)
Common Stock, par value \$.0001 per share 03/29/				03/29/20	2017 A 28,725 ⁽¹⁾ A		4	\$ <mark>0</mark>	57,450			D						
			Table II - D			urities <i>A</i> ls, warra								wned				
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	e (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	saction (Instr.			6. Date Exercisable and Expiration Date (Month/Day/Year)		e	7. Title and Am of Securities Underlying Derivative Sec (Instr. 3 and 4)		1	B. Price of Derivative Security Instr. 5)	9. Number derivative Securities Beneficial Owned Following Reported	ly	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownership (Instr. 4)
				Code	· V	(A)	(D)	Date Exercisal	ole	Expiration Date	Title	Amou or Numb of Share	oer		Transaction(s) (Instr. 4)			
Option to Purchase Common Stock	\$118.83	03/29/2017		A		56,762 ⁽²⁾		03/27/20	18	03/27/2027	Common Stock, par value \$.0001 per share	56,7	62	\$0	56,762	2	D	

Explanation of Responses:

- 1. Award of Restricted Stock Units under the 2004 Incentive Plan. Vests 25% on each of December 31, 2017, December 31, 2018, March 27, 2020, and March 27, 2021.
- 2. Stock option award under 2004 Incentive Plan. Vests 25% on the first anniversary of the grant date, 1/16 every three months thereafter until fully vested over 4 years.

Remarks:

<u>Michael V. Greco, Attorney-in-fact for Ludwig Hantson</u>

03/29/2017

** Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.